140 related articles for article (PubMed ID: 121170)
1. [Blood derivatives in the treatment of hemophilia in Spain. Present and future needs].
Medarde A; Ayesa C; Alfonso L; Muñóz A
Sangre (Barc); 1979; 24(5-C):942-6. PubMed ID: 121170
[No Abstract] [Full Text] [Related]
2. Letter: Blood fractions for haemophilia.
Aledort LM
Lancet; 1974 Dec; 2(7894):1452. PubMed ID: 4140363
[No Abstract] [Full Text] [Related]
3. Factor products in the treatment of hemophilia.
Miller KL
J Pediatr Health Care; 2004; 18(3):156-7. PubMed ID: 15129219
[No Abstract] [Full Text] [Related]
4. Advances in the care and treatment of children with hemophilia.
Manco-Johnson MJ
Adv Pediatr; 2010; 57(1):287-94. PubMed ID: 21056743
[No Abstract] [Full Text] [Related]
5. [Substitution therapy of hemorrhagic diseases].
Haupt H
Anasthesiol Intensivmed Prax; 1975 Oct; 11(1):137-44. PubMed ID: 1225069
[No Abstract] [Full Text] [Related]
6. Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.
Limentani SA
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S81-4. PubMed ID: 7795145
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of hemophilia].
Stavem P; Hjort PF
Tidsskr Nor Laegeforen; 1970 Jul; 90(13):1413-8. PubMed ID: 5453192
[No Abstract] [Full Text] [Related]
8. Specific therapy in hemophilia.
Hutaff LW
N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809
[No Abstract] [Full Text] [Related]
9. [Substitution therapy with factor 8 and factor IX preparations].
Landbeck G
Hamatol Bluttransfus; 1968; 5():29-42. PubMed ID: 5729465
[No Abstract] [Full Text] [Related]
10. Treatment of hemophiliacs with inhibitors: cost and effect on blood resources.
Aledort LM; Cohen M; Hilgartner M; Lipton R
Prog Clin Biol Res; 1984; 150():353-65. PubMed ID: 6431439
[No Abstract] [Full Text] [Related]
11. [Substitution treatment in hemophilia. Critical measures and complications].
Schimpf K
Wien Med Wochenschr; 1977 Jun; 127(11):329-37. PubMed ID: 878496
[No Abstract] [Full Text] [Related]
12. Treatment of haemophilia.
Ludlam CA
Br J Haematol; 1998 May; 101 Suppl 1():13-4. PubMed ID: 9607736
[No Abstract] [Full Text] [Related]
13. Hemophilia treatment: its relationship to blood products.
Aledort LM; Goodnight SH
Prog Hematol; 1981; 12():125-41. PubMed ID: 6803297
[No Abstract] [Full Text] [Related]
14. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
István L; Bariska I; Marton E
Orv Hetil; 1980 Dec; 121(51):3131-5. PubMed ID: 6784062
[No Abstract] [Full Text] [Related]
15. The current approach to hemophilia.
Morrison CJ
J Maine Med Assoc; 1974 Sep; 65(9):205-6. PubMed ID: 4416140
[No Abstract] [Full Text] [Related]
16. [Oral administration of factor VIII or IX concentrate preparation].
Sakuragawa N
Rinsho Ketsueki; 1985 Jul; 26(7):1086-9. PubMed ID: 3932721
[No Abstract] [Full Text] [Related]
17. Production of antihemophilic factor in France.
Allain JP
Scand J Haematol Suppl; 1984; 40():499-503. PubMed ID: 6433471
[No Abstract] [Full Text] [Related]
18. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
Triginer J; Vila M; Vicente Arangüena P
Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
[No Abstract] [Full Text] [Related]
19. [Study of the "in vivo" activity of factor VIII or factor IX after injection of several concentrates: practical applications].
Allain JP
Nouv Rev Fr Hematol; 1972; 12(2):241-9. PubMed ID: 4264617
[No Abstract] [Full Text] [Related]
20. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
[No Abstract] [Full Text] [Related]
[Next] [New Search]
